Cryoport’s (CYRX) “Buy” Rating Reiterated at Roth Mkm

Roth Mkm reaffirmed their buy rating on shares of Cryoport (NASDAQ:CYRX) in a report issued on Tuesday morning,Benzinga reports. Roth Mkm currently has a $15.00 target price on the stock.

A number of other analysts also recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Cryoport in a research report on Monday. UBS Group boosted their target price on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Guggenheim initiated coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.83.

Cryoport Stock Performance

NASDAQ:CYRX opened at $6.09 on Tuesday. The business’s fifty day moving average is $6.61 and its 200 day moving average is $7.28. The firm has a market cap of $303.95 million, a price-to-earnings ratio of -1.80 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport has a 52-week low of $4.58 and a 52-week high of $20.11.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the previous year, the company posted ($0.29) earnings per share. Research analysts predict that Cryoport will post -0.99 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders sold 19,830 shares of company stock worth $118,353. 10.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cryoport

A number of institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC bought a new position in Cryoport in the 3rd quarter worth about $105,000. Charles Schwab Investment Management Inc. raised its holdings in Cryoport by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after buying an additional 2,226 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Cryoport in the third quarter worth approximately $82,000. Point72 Asset Management L.P. purchased a new stake in shares of Cryoport during the third quarter valued at approximately $3,405,000. Finally, Stifel Financial Corp increased its position in shares of Cryoport by 11.0% during the third quarter. Stifel Financial Corp now owns 139,745 shares of the company’s stock valued at $1,133,000 after acquiring an additional 13,809 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.